Treatment & Prevention of Non-Melanoma Skin Cancer with Laser in the Next 1-5 Years

The presentation discusses advancements in non-invasive treatment options for non-melanoma skin cancer, particularly using laser technology for effective tumor regression. Initial studies conducted since 2011 demonstrated significant clearance rates of basal cell carcinoma through selective targeting of tumor vasculature using various lasers, such as the pulsed dye laser and the NDAG 1064 nanometer laser, achieving clearance rates of approximately 90-92%. Additionally, the incorporation of lidocaine with fractional lasers has shown potential in enhancing the effectiveness of hyperthermic therapy, resulting in increased cancer cell death while preserving normal tissue. Another promising approach involves the use of gold nanoparticles designed to specifically target basal cell carcinoma and enhance laser treatment efficacy with minimized side effects, although this is still in animal testing stages. Furthermore, findings suggest that prior fractional laser treatments can significantly reduce the incidence and recurrence of basal cell carcinoma in patients with a history of the disease. The research points to many areas of ongoing inquiry, including optimal treatment intervals and the broader health benefits of laser therapy, underscoring the potential of these technologies in improving skin cancer management and prevention.